Systematic Financial Management LP Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN

Systematic Financial Management LP grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2,269.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 254,400 shares of the biotechnology company’s stock after acquiring an additional 243,665 shares during the period. Systematic Financial Management LP’s holdings in BioMarin Pharmaceutical were worth $15,119,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BMRN. Activest Wealth Management purchased a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at $26,000. Smartleaf Asset Management LLC raised its stake in shares of BioMarin Pharmaceutical by 92.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 360 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at $40,000. Parallel Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 295 shares during the period. Finally, V Square Quantitative Management LLC purchased a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at $45,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

Analyst Upgrades and Downgrades

BMRN has been the topic of a number of research reports. Jefferies Financial Group reissued a “buy” rating and issued a $103.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. Bank of America cut their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wells Fargo & Company lifted their price target on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Guggenheim dropped their price target on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Finally, Wall Street Zen raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $88.67.

Insider Activity

In other news, EVP Charles Greg Guyer sold 16,486 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the sale, the executive vice president owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregory R. Friberg sold 3,281 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the completion of the sale, the executive vice president directly owned 51,818 shares of the company’s stock, valued at $2,790,399.30. The trade was a 5.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 26,093 shares of company stock valued at $1,555,389 in the last three months. Insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Price Performance

BMRN opened at $54.09 on Monday. The company has a 50-day moving average of $54.56 and a 200-day moving average of $56.27. The company has a market capitalization of $10.45 billion, a P/E ratio of 39.48, a PEG ratio of 0.41 and a beta of 0.23. BioMarin Pharmaceutical Inc. has a 1-year low of $49.26 and a 1-year high of $66.28. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.